{
    "clinical_study": {
        "@rank": "100696", 
        "arm_group": {
            "arm_group_label": "Stem cell treated", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem\n      cells from bone marrow into the eye as treatment for patients who are irreversibly blind\n      from various retinal conditions."
        }, 
        "brief_title": "Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Dry Age-related Macular Degeneration", 
            "Diabetic Retinopathy", 
            "Retina Vein Occlusion", 
            "Retinitis Pigmentosa", 
            "Hereditary Macular Degeneration"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Retinopathy", 
                "Macular Degeneration", 
                "Retinal Diseases", 
                "Retinitis", 
                "Retinitis Pigmentosa"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this pilot clinical trial, eyes with irreversible vision loss from retinal degenerative\n      conditions (macular degeneration or retinitis pigmentosa) or retinal vascular disease\n      (diabetic retinopathy or retinal vein occlusion) will be treated with intravitreal injection\n      of autologous CD34+ stem cells isolated from bone marrow aspirate under Good Manufacturing\n      Practice conditions.  This study will determine whether there are any major safety and\n      feasibility concerns using this therapy.  Patients will be followed for 6 months after\n      treatment by serial comprehensive eye examination supplemented with various retinal imaging\n      and diagnostic tests."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age >18 years of age\n\n          -  visual acuity 20/200 to CF\n\n          -  duration of vision loss > 3 months\n\n          -  vision loss from macular degeneration, retinitis pigmentosa, retinal vein occlusion\n             or diabetic retinopathy\n\n          -  the study eye has the worse visual acuity\n\n          -  no active eye or systemic disease\n\n          -  no history of macular edema or retinal/choroidal neovascularization requiring\n             treatment within 6 months\n\n          -  no significant media opacity\n\n          -  no coagulopathy or other hematologic abnormality\n\n          -  no concurrent immunosuppressive therapy\n\n          -  able to keep follow-up for 6 months\n\n        Exclusion Criteria:\n\n          -  allergy to fluorescein dye\n\n          -  other concurrent retinal or optic nerve disease affecting vision"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736059", 
            "org_study_id": "BMSCRetPilot"
        }, 
        "intervention": {
            "arm_group_label": "Stem cell treated", 
            "intervention_name": "CD34+ bone marrow stem cells intravitreal", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Stem cells", 
            "intravitreal", 
            "bone marrow CD34+ cells", 
            "retinal disease", 
            "clinical trial", 
            "autologous"
        ], 
        "lastchanged_date": "February 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sacramento", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "95817"
                }, 
                "name": "University of California Davis"
            }, 
            "investigator": [
                {
                    "last_name": "Lawrence S Morse, MD PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jan Nolta, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Gerhard Bauer", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Carol Richman, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mehrdad Abedi, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Douglas Taylor, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes With Vision Loss From Retinopathy", 
        "other_outcome": {
            "description": "Any systemic adverse event attributable to the bone marrow aspiration or intravitreal injection of the stem cells.", 
            "measure": "Incidence and severity of systemic adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "1 day to 6 months"
        }, 
        "overall_contact": {
            "email": "susanna.park@ucdmc.ucdavis.edu", 
            "last_name": "Susanna S Park, MD PhD", 
            "phone": "916-734-6074"
        }, 
        "overall_contact_backup": {
            "email": "marisa.salvador@ucdmc.ucdavis.edu", 
            "last_name": "Marisa Salvador", 
            "phone": "916-734-6302"
        }, 
        "overall_official": {
            "affiliation": "University of California Davis Eye Center", 
            "last_name": "Susanna s Park, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "As evident on eye examination by severe decrease in vision and/or adverse effect requiring major treatment intervention directly attributable to study treatment.", 
            "measure": "Incidence and severity of ocular adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "1 day to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736059"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Will determine the yield of the bone marrow aspiration and stem cell isolation procedures.", 
            "measure": "The number of stem cells isolated and injected into the study eye", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "source": "University of California, Davis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of California, Davis", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}